Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
Acute Bronchodilation and Bronchial Inflammation: Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients. Stretching of Airways and Nitric Oxide in Bronchodilation, SANOB Study
- Among many other causes, Bronchial obstruction in Chronic Obstructive Pulmonary Disease
(COPD) is also caused by inflammation of peripheral airways walls.
- Neutrophils and other inflammatory mediators like Interleukin-6 (IL6), Interleukin-8
(IL8), Interleukin-1 alpha (IL-1 alpha),Interleukin-1beta (IL-1 beta), Tumor Necrosis
Factor alfa (TNF-alfa), Reactive Oxygen Species (ROS), Leukotriene B4 (LTB4), Nitric
Oxyde (NO) are implicated in the inflammation.
- NO is produced in response to physical and chemical stress on bronchial epithelium and
plays a critical role in small airways remodelling
- Exhaled NO concentration is usually used to monitor bronchial inflammation
- The relationship between stretch and strain of small airways and bronchial inflammation
is not well understood.
- The investigators hypothesis is that cyclic opening and closure of peripheral
obstructed airways through the consequent stretching and strain acting on them can
provoke an inflammatory response which can be monitored by exhaled NO.
- The pharmacological effects of bronchodilators may play a role on bronchial
inflammation by reducing the stretching stress on bronchiolar walls thus reducing the
production of NO in exhalate
- Data about these physiopathological aspects is missing in literature.
Bronchial inflammation in COPD represents one of the main causes of not fully reversible
obstruction and airflow limitation. The main inflammatory cells involved are represented by
the neutrophils, while some inflammatory mediators like Interleukin-6 (IL6), Interleukin-8
(IL8), Interleukin-1 alpha (IL1alpha), Interleukin-1 beta (IL1beta), Tumor Necrosis Factor
alfa (TNFalfa), Reactive Oxygen Species (ROS), Leukotriene B4 (LTB4) and Nitric Oxide (NO)
provoke the disruption of the elastic alveolar bonds that support the small airways, thus
invalidating their physical and mechanical characteristics. During tidal volume respiration,
in such patients, the chronically obstructed small airways are subjected, the investigators
suppose, to one of the following effects:
- a total closure of the smaller bronchioli causing atelectasis
- a cyclic opening and closure of the airways thus provoking friction and strain stress
and an inflammatory response of mechanical origin.
The Fraction of Exhaled Nitric Oxyde (FeNO) concentration is largely used in clinical
practice as a marker to monitor the lung inflammatory status. Formoterol and Salmeterol are
two of the most used Long Acting Beta 2 Agonists (LABA) for inhaled therapy of COPD,
representing the basis of the bronchodilator therapy in this disease.
The purpose of the study is to evaluate the possible mechanical origin of the bronchial
inflammation and then the capacity of inhaled LABA in acute conditions to modify the trend
of production of NO by reducing stretching and strain forces. Thus the possible decline of
exhaled NO concentration will be used as an index of the small airways inflammatory state
occurring after inhaled therapy.
To do this the investigators will measure the exhaled NO concentration in COPD patients with
moderate to severe obstruction, that is a Forced Expiratory Volume less than 70% of
predicted value (FEV1<70%pred). The evaluation will be done in four different moments:
1. at baseline, after 72 hours of pharmacological washout conditions
2. at 30 minutes after the assumption of inhaled therapy (Salmeterol 50 mcg or Formoterol
12 mcg in double blind conditions)
3. at 60 minutes after step 2
4. at 180 minutes after step 2 Together with NO concentration, also the Respiratory
Frequency and Tidal Volume will be registered during each evaluation.
All the subjects will be inpatients accessing a respiratory rehabilitation unit or
outpatients of the ambulatory service. After every NO measure, a functional respiratory
assessment will be made (spirometry, plethysmography, Carbon Monoxide (CO) diffusion lung
test, Single Breath N2 washout test), together with an arterial blood gas analysis.
At every step a dyspnoea assessment will be made by Visual Analogic Scale, while Modified
Medical Research Council (mMRC) scale will be assessed at the beginning of the test.
Every patient will repeat the four step assessment after 72 hours, while a double blind
pharmacological crossover will be performed, thus creating a controlled study in witch every
patients, at the end of the study, will take Salmeterol and Formoterol in a randomized way.
For the study duration all the patients will perform a pharmacological washout (living the
short acting inhaled Beta 2 agonists as rescue medication)
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |